Artivion, Inc. (NYSE:AORT) Given Average Recommendation of “Buy” by Analysts

Shares of Artivion, Inc. (NYSE:AORT) have been assigned a consensus rating of “Buy” from the six brokerages that are covering the firm, MarketBeat reports. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $31.40.

A number of brokerages have recently weighed in on AORT. Stifel Nicolaus lowered their target price on Artivion from $33.00 to $30.00 and set a “buy” rating on the stock in a report on Tuesday, February 25th. JMP Securities reaffirmed a “market outperform” rating and set a $33.00 target price on shares of Artivion in a research report on Tuesday. Needham & Company LLC reiterated a “buy” rating and issued a $32.00 target price on shares of Artivion in a research note on Tuesday. Finally, Citizens Jmp upgraded Artivion to a “strong-buy” rating in a research note on Tuesday.

Artivion Stock Performance

Artivion stock opened at $27.45 on Wednesday. The firm’s 50 day simple moving average is $23.96 and its 200-day simple moving average is $27.18. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.88 and a quick ratio of 1.33. Artivion has a fifty-two week low of $21.97 and a fifty-two week high of $32.33. The company has a market cap of $1.17 billion, a P/E ratio of -1,372.55 and a beta of 1.54.

Artivion (NYSE:AORT) last announced its quarterly earnings data on Monday, May 5th. The company reported $0.06 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.12 by ($0.06). The firm had revenue of $98.98 million for the quarter, compared to analysts’ expectations of $94.81 million. Artivion had a positive return on equity of 5.15% and a negative net margin of 0.22%. As a group, equities research analysts predict that Artivion will post 0.37 EPS for the current year.

Insider Transactions at Artivion

In other Artivion news, SVP Jean F. Holloway sold 18,020 shares of the stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $23.61, for a total transaction of $425,452.20. Following the sale, the senior vice president now owns 197,184 shares of the company’s stock, valued at $4,655,514.24. This represents a 8.37 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO James P. Mackin sold 42,156 shares of the business’s stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $27.31, for a total transaction of $1,151,280.36. Following the completion of the transaction, the chief executive officer now directly owns 663,882 shares of the company’s stock, valued at approximately $18,130,617.42. This represents a 5.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 90,799 shares of company stock valued at $2,356,223 in the last three months. 7.60% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Smartleaf Asset Management LLC increased its holdings in Artivion by 236.7% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,118 shares of the company’s stock valued at $32,000 after purchasing an additional 786 shares during the last quarter. Legacy Advisors LLC bought a new stake in shares of Artivion in the 1st quarter valued at about $28,000. MCF Advisors LLC increased its stake in shares of Artivion by 109.3% in the 1st quarter. MCF Advisors LLC now owns 1,176 shares of the company’s stock valued at $29,000 after acquiring an additional 614 shares during the last quarter. R Squared Ltd bought a new position in Artivion during the 4th quarter worth approximately $39,000. Finally, Arcadia Investment Management Corp MI bought a new position in Artivion during the 4th quarter worth approximately $43,000. Institutional investors own 86.37% of the company’s stock.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.